Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.
Find University Hospitals Doctors
Gulgun Yalcinkaya, MD

Gulgun Yalcinkaya, MD

  • Medical Director, NICU Step Down Unit, UH Rainbow Babies and Children's Hospital
  • Assistant Professor, CWRU School of Medicine
  • Specialty: Neonatology
  • Location:
    UH Landerbrook Health Center
    5850 Landerbrook Dr
    Mayfield Heights, OH 44124

Biography: Gulgun Yalcinkaya, MD

Expertise

  • Neonatology

Certifications & Memberships

  • Neonatal/Perinatal Medicine - American Board of Pediatrics
  • Pediatrics - American Board of Pediatrics

Education

Fellowship | Neonatal-Perinatal Medicine
Neonatal-Perinatal Medicine - New York University School Of Medicine And Langone Medical Center (1994 - 1997)

Residency | Pediatrics
Pediatrics - New York University School Of Medicine And Langone Medical Center (1992 - 1994)

Internship | Pediatrics
Pediatrics - New York University School Of Medicine And Langone Medical Center (1991 - 1992)

Medical Education
Istanbul Universitesi Cerrahpasa Tip Fakultesi (1989)

About

Gulgun Yalcinkaya, MD received her medical education at Istanbul Universitesi Cerrahpasa Tip Fakultesi in Turkey and went on to complete her pediatric residency and fellowship at New York University Medical Center. Dr. Yalcinkaya is involved with neonatal follow-up clinic and is co-director of the Transitional Care Nursery. Dr. Yalcinkaya is the Director of MS3 Neonatology Medical Education and also oversees the Neonatal Observership Program.

Industry Relationships

University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.

UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.

View UH’s policy (PDF) on practitioner-industry relationships.

As of December 31, 2016, Gulgun Yalcinkaya did not disclose any Outside Relationships with Industry.